milk thistle reduces 1gf 1?

[henryhairyballs]

saw this on a thread a sec ago.. any evidence???

[CaptAppleJax]

Heard/saw the same thing... I just stopped taking it when I read it and kept my liv52 going.

[henryhairyballs]

Wierd.. I take 1000mg a day when taking oral AAs. Ima look more into that.

[henryhairyballs]

i found this on google... thats about it...



Silymarin is a mixture of three flavonolignans of which silybinin is the dominant compound. In the present study, the estrogenic effects of SIL on various body organs as well as on markers of bone remodeling in an OVX rat model of postmenopausal bone loss have been evaluated. A marked atrophy of the uterus has been used as evidence of the success of ovariectomy, because estrogen directly influences uterine weight (Hidakaetal., 2006). In the first step of the present study the uterotropic potential of silymarin has been evaluated. Our results showed that animals administered SIL had significantly higher uterine weights compared to the OVX rats. This effect was; however, 6.48 times lower in magnitude compared to the effects of EE. In addition, uterotrophic effects of SIL were also evident from increased uterus hyperplastic endometrial glands. Significant increases of uterine weight and endometrial height, as well as hypertrophy of luminal epithelium, have been established as reliable indexes of estrogenic effects (Tinwell et al., 2000). Hence, it could be suggested that SIL influenced the actions of estrogen or its receptor in the uterus. No significant binding capacity to the ERa or an increase in uterineweight in OVX rat has been observed, following one-week s.c. treatment with SIL (Seidlova-Wuttke et al., 2003a). However, Sonnenbichler et al. (1999) reported a partial binding capacity of silybin to the ER[alpha]. Moreover, in previous study, uterotrophic effects of 30-day treatment with SIL were evident from increased heights of the luminal epithelium and endometrium; a highly significant decrease of density of ER[alpha], another hallmark of estrogenic activity, was also found in the luminal and glandular endometrial epithelia of OVX rats (Kummer et al., 2001, Pliskova et al., 2005). These findings are in accordance with data obtained in this study. In the uterus ER[alpha] and ER were both present in epithelial cells lining the lumen and glands (Saunders et al., 1997).

In postmenopausal women, uterotropic effects of estrogen therapy are undesirable since they stimulate endometrial hyperplasia and may increase the risk of endometrial cancer (Weider-pass et al., 1999).[B] Hence, it is also possible that uncontrolled SIL intake could endanger women endometrium to become hyperplasic. Further studies are, however, warranted to evaluate the actual risk.